Please try another search
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Barry E. Greene | 58 | 2020 | President, CEO & Director |
James M. Frates | 55 | 2014 | Independent Director |
Michael F. Cola | 62 | 2014 | Independent Director |
Charles Zorumski | - | - | Member of Scientific Advisory Board |
Steven M. Paul | 73 | 2011 | Independent Director |
Stephen Moss | - | - | Member of Scientific Advisory Board |
Donald Stein | - | - | Member of Scientific Advisory Board |
David H. Farb | - | - | Member of Scientific Advisory Board |
Elizabeth A. Barrett | 62 | 2019 | Independent Director |
George S. Golumbeski | 67 | 2019 | Independent Director |
Stephen F. Traynelis | - | - | Member of Scientific Advisory Board |
Christine Marx | - | - | Member of Scientific Advisory Board |
Scott Runyon | - | - | Member of Scientific Advisory Board |
A. Leslie Morrow | - | - | Member of Scientific Advisory Board |
Michael A. Rogawski | - | - | Member of Scientific Advisory Board |
Jeffrey M. Jonas | 71 | 2013 | Outside Non-Employee Member of CNS Innovation Advisory Board & Director |
James E. Audia | 68 | - | Member of Scientific Advisory Board |
Jessica J. Federer | 41 | 2023 | Independent Director |
Geno J. Germano | 63 | 2016 | Independent Chair of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review